Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Edara, V. V.; Norwood, C.; Floyd, K.; Lai, L.; Davis-Gardner, M. E.; Hudson, W. H.; Mantus, G.; Nyhoff, L. E.; Adelman, M. W.; Fineman, R.; Patel, S.; Byram, R.; Gomes, D. N.; Michael, G.; Abdullahi, H.; Beydoun, N.; Panganiban, B.; McNair, N.; Hellmeister, K.; Pitts, J.; Winters, J.; Kleinhenz, J.; Usher, J.; O'Keefe, J. B.; Piantadosi, A.; Waggoner, J. J.; Babiker, A.; Stephens, D. S.; Anderson, E. J.; Edupuganti, S.; Rouphael, N.; Ahmed, R.; Wrammert, J.; Suthar, M. S.
Show abstract
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination 97%
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants 97%
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 96%
Similar papers in this journal
- Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity 95%
- Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection 95%
- Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. 94%
Similar papers in this journal
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 96%
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 96%
- Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting. 95%
Similar papers in this journal
- The Omicron variant is highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 pandemic 97%
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity 96%
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant 96%
Similar papers in this journal
- Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection 96%
- Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 96%
- Versatile live attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.